Supply Chain Management in the Drug Industry – Delivering Patient Value for Pharmaceuticals and Biologics

Delivering Patient Value for Pharmaceuticals and Biologics

Gebonden Engels 2011 9780470555170
Verwachte levertijd ongeveer 9 werkdagen

Samenvatting

This book bridges the gap between practitioners of supply–chain management and pharmaceutical industry experts. It aims to help both these groups understand the different worlds they live in and how to jointly contribute to meaningful improvements in supply–chains within the globally important pharmaceutical sector. Scientific and technical staff must work closely with supply–chain practitioners and other relevant parties to help secure responsive, cost effective and risk mitigated supply chains to compete on a world stage. This should not wait until a drug has been registered, but should start as early as possible in the development process and before registration or clinical trials. The author suggests that CMC (chemistry manufacturing controls) drug development must reset the line of sight from supply of drug to the clinic and gaining a registration, to the building of a patient value stream. Capable processes and suppliers, streamlined logistics, flexible plant and equipment, shorter cycle times, effective flow of information and reduced waste. All these factors can and should be addressed at the CMC development stage.

Specificaties

ISBN13:9780470555170
Taal:Engels
Bindwijze:gebonden
Aantal pagina's:458

Lezersrecensies

Wees de eerste die een lezersrecensie schrijft!

Inhoudsopgave

<p>CONTRIBUTORS xiii</p>
<p>PREFACE xxi</p>
<p>I SURVEYING AND MAPPING THE TERRITORY 1</p>
<p>1 Setting a Transformational Agenda 3</p>
<p>1.1 Aims and Aspirations of the Book 3</p>
<p>1.2 Book Format 5</p>
<p>1.3 Intended Readership 6</p>
<p>1.4 A Book About Two Worlds in Contrast 8</p>
<p>1.5 The Pharmaceutical Lottery 8</p>
<p>1.6 Supply Chain Management in Context 17</p>
<p>1.7 The History of Supply and Value Generation 22</p>
<p>1.8 The Development of Processes to Manage the Supply Chain 24</p>
<p>1.9 Life in SCM 25</p>
<p>1.10 Moving Forward 26</p>
<p>2 Plotting a Course to Patient Value 29</p>
<p>2.1 Why Focus on Patient Value? 29</p>
<p>2.2 Where Does the Patient Currently Fit? 29</p>
<p>2.3 Why Is It Necessary to Plot a Course? 33</p>
<p>2.4 Understanding How the Course Is Presently Set 39</p>
<p>2.5 Capturing Value for Patients 42</p>
<p>3 Pharmaceutical Drug Development 45</p>
<p>3.1 Drug Development s Role in the Supply Chain 45</p>
<p>3.2 Introduction to Drug Development 47</p>
<p>3.3 The Medicinal Product 48</p>
<p>3.4 Clinical Trials 49</p>
<p>3.5 Related Development Programs 52</p>
<p>3.6 Managing Clinical Programs 57</p>
<p>3.7 Regulatory Affairs and Authorities 58</p>
<p>3.8 Supply Chain Management in Development Programs 65</p>
<p>3.9 Manufacture and Supply of Commercial Products 68</p>
<p>3.10 Supply Chain Management for Commercial Products 69</p>
<p>4 End–to–End Pharmaceutical Supply Chains 73</p>
<p>4.1 Introduction 73</p>
<p>4.2 Where Does Responsibility for the Supply Chain Lay? 74</p>
<p>4.3 Sponsoring Companies, License Holders, and Their Supply Chains 75</p>
<p>4.4 Supply Chains for Small–Molecule Products 76</p>
<p>4.5 Starting at the Final Destination 78</p>
<p>4.6 How Drugs Enter the Body 78</p>
<p>4.7 Design of Drug Delivery Systems 79</p>
<p>4.8 What This Means for the Supply Chain 82</p>
<p>4.9 Key Aspects of GMP and GDP in Relation to SCM 82</p>
<p>4.10 Overview of the Stages on Route to Patient Delivery 86</p>
<p>4.11 Manufacture and Supply of Biological Entities 90</p>
<p>5 Why Pharma Supply Chains Don t Perform 103</p>
<p>5.1 Supply Chain Underperformance 103</p>
<p>5.2 Is There a Case to Answer? 103</p>
<p>5.3 Birth to Infancy: The Supply Chain Critical Stage 104</p>
<p>5.4 Commercial Supply Under the Patent Protection Umbrella 111</p>
<p>5.5 What This Means for the Pharmaceutical Supply Chain 116</p>
<p>II BUILDING A KNOWLEDGE FOUNDATION IN SCM 125</p>
<p>6 Supply Chain Management as a Competitive Weapon 127</p>
<p>6.1 Competition and Business Strategy 127</p>
<p>6.2 The Marketing Mix 128</p>
<p>6.3 Porter s Five Forces 128</p>
<p>6.4 Porter s Generic Competitive Strategies 129</p>
<p>6.5 Porter s Value Chain 129</p>
<p>6.6 Competitive Strategy and Customers 133</p>
<p>6.7 The Japanese Experience 142</p>
<p>6.8 Total Quality Management 142</p>
<p>6.9 Lean Thinking 143</p>
<p>6.10 Focusing on Value for Money 146</p>
<p>6.11 SCM Processes in Competitive Strategy 148</p>
<p>6.12 SCM in Biotech and Virtual Companies 150</p>
<p>6.13 Competition in Pharmaceuticals 152</p>
<p>7 Supply Chain Management Holistic 155</p>
<p>7.1 The Relevance of SCM to Pharmaceuticals 155</p>
<p>7.2 Production Systems and the SCM Holistic 155</p>
<p>7.3 The Core of SCM 156</p>
<p>7.4 First Principle of SCM 156</p>
<p>7.5 Supply Chains as a Series of Interconnected Systems 158</p>
<p>7.6 Processes to Manage the Supply Chain 160</p>
<p>7.7 A Word About Processes 161</p>
<p>7.8 How the SCM Processes Should Mesh Together 163</p>
<p>7.9 Production and Inventory Control 163</p>
<p>7.10 Strategic Procurement 163</p>
<p>7.11 Transportation, Storage, and Distribution 164</p>
<p>7.12 Information Systems and Technology 164</p>
<p>7.13 Improvement 165</p>
<p>8 Production and Inventory Control 167</p>
<p>8.1 Core Mission 167</p>
<p>8.2 First Principles of Production and Inventory Control 167</p>
<p>8.3 The Wholesome Trinity in P&amp;IC 174</p>
<p>8.4 The Wholesome Trinity and Customer Expectations 177</p>
<p>8.5 Leveraging the Wholesome Trinity 179</p>
<p>8.6 The Impact of Variety on Supply Chains 180</p>
<p>8.7 Designing Appropriate Production Systems 183</p>
<p>9 Strategic Procurement 187</p>
<p>9.1 Core Mission 187</p>
<p>9.2 The Purchasing Portfolio 188</p>
<p>9.3 The Process of Procurement 195</p>
<p>9.4 Strategic Sourcing and Planning 198</p>
<p>9.5 Outsourcing 201</p>
<p>9.6 Basic Principles in Contracting for Supply 206</p>
<p>9.7 Finally, Typical Organizational Tension over Procurement 213</p>
<p>10 Transportation, Storage, and Distribution 215</p>
<p>10.1 Defining the Core Mission 215</p>
<p>10.2 International Trade and Commerce 217</p>
<p>10.3 The World Trade Organization 217</p>
<p>10.4 Intermediary Arrangements 220</p>
<p>10.5 Terms of Trade: Incoterms 223</p>
<p>10.6 Ownership of Goods: Title 225</p>
<p>10.7 Third–Party Logistics Providers 226</p>
<p>10.8 Customs 227</p>
<p>10.9 Shipping Regulations Relating to Materials 229</p>
<p>10.10 A Finishing Note 230</p>
<p>11 Information Systems and Information Technology 233</p>
<p>11.1 Overview 233</p>
<p>11.2 Brief Lay History of Computer Systems Development 234</p>
<p>11.3 Important Perspectives on Information Systems 236</p>
<p>12 Improvement 255</p>
<p>12.1 Why Improve? 255</p>
<p>12.2 Improvement and Production Systems 257</p>
<p>12.3 The Improvement Journey 258</p>
<p>13 Bringing the Holistic Together 277</p>
<p>13.1 Setting the Scene 277</p>
<p>13.2 The Process Explained 278</p>
<p>13.3 Developing an Action Agenda 285</p>
<p>13.4 Case Study 289</p>
<p>III PLANNING AND EXECUTING SUPPLY CHAIN CHANGE 293</p>
<p>14 Improvement in Pharmaceuticals 295</p>
<p>14.1 Where Are We Now? 295</p>
<p>14.2 Subsequent Developments Since Inception 310</p>
<p>14.3 A Blueprint for Quality by Design 311</p>
<p>15 Exemplar Thinking in Organizational Improvement 335</p>
<p>15.1 Where Are We Now? 335</p>
<p>15.2 What Is Meant by "Exemplar"? 338</p>
<p>15.3 A Dialogue on Exemplar Improvement 338</p>
<p>15.4 An Approach to SCM Based on Systems Thinking 357</p>
<p>16 Building a Foundation for Sustainable Change 363</p>
<p>16.1 Focus on the Individual 363</p>
<p>16.2 Individuals as Leaders 368</p>
<p>16.3 Individuals as Motivators and the Motivated 370</p>
<p>16.4 Individuals as Group Members 372</p>
<p>16.5 Individuals as Participants in Cultural Change 376</p>
<p>16.6 Case Study: Miles Ltd., Bridgend, Glamorgan 378</p>
<p>17 A Cure for the Pharmaceutical Supply Chain 395</p>
<p>17.1 What Is the Disease State? 395</p>
<p>17.2 What Is the Label Claim for the Medicine? 396</p>
<p>17.3 What Will Life Hold Without the Medicine? 397</p>
<p>17.4 What Is This Better Way to Develop Drugs? 397</p>
<p>17.5 Full–Scale Production of Drugs 407</p>
<p>17.6 What Are the Barriers to Change? 410</p>
<p>17.7 What Are the Potential Benefits of Change? 413</p>
<p>17.8 Defining the Art of the Possible 414</p>
<p>17.9 Ending with the Beginning 417</p>
<p>END NOTES 419</p>
<p>INDEX 429</p>

Managementboek Top 100

Rubrieken

Populaire producten

    Personen

      Trefwoorden

        Supply Chain Management in the Drug Industry – Delivering Patient Value for Pharmaceuticals and Biologics